Aspirin dilemma. Remodelling the hypothesis from a fertility perspective

O. Ozturk, Michael Greaves, Alexander Allan Templeton

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Many clinical trials in obstetrics have failed to demonstrate improved outcomes with low-dose aspirin. This is not entirely surprising as prescribing aspirin for compromised tissue perfusion without insight into underlying pathology inevitably leads to suboptimal outcomes. We argue that a mismatch between the aspirin dose and the underlying pathology of altered tissue perfusion is the key factor to this failure. Based on this groundwork, we address the question of how best to optimize the dose of aspirin for use in fertility management, by providing examples from the assisted conception and recurrent miscarriage settings.

Original languageEnglish
Pages (from-to)1146-1148
Number of pages2
JournalHuman Reproduction
Volume17
Issue number5
DOIs
Publication statusPublished - 2002

Keywords

  • aspirin
  • fertility
  • IVF
  • miscarriages
  • prostaglandins
  • IN-VITRO FERTILIZATION
  • LOW-DOSE ASPIRIN
  • ANTIPHOSPHOLIPID ANTIBODIES
  • EMBRYO-TRANSFER
  • RECURRENT MISCARRIAGE
  • PREGNANCY RATES
  • PROSTAGLANDIN ENDOPEROXIDES
  • AUTOIMMUNE ANTIBODIES
  • INVITRO FERTILIZATION
  • UTERINE PERFUSION

Cite this

Aspirin dilemma. Remodelling the hypothesis from a fertility perspective. / Ozturk, O.; Greaves, Michael; Templeton, Alexander Allan.

In: Human Reproduction, Vol. 17, No. 5, 2002, p. 1146-1148.

Research output: Contribution to journalArticle

@article{bcf92d8c8a764787a91d15966ecc0a64,
title = "Aspirin dilemma. Remodelling the hypothesis from a fertility perspective",
abstract = "Many clinical trials in obstetrics have failed to demonstrate improved outcomes with low-dose aspirin. This is not entirely surprising as prescribing aspirin for compromised tissue perfusion without insight into underlying pathology inevitably leads to suboptimal outcomes. We argue that a mismatch between the aspirin dose and the underlying pathology of altered tissue perfusion is the key factor to this failure. Based on this groundwork, we address the question of how best to optimize the dose of aspirin for use in fertility management, by providing examples from the assisted conception and recurrent miscarriage settings.",
keywords = "aspirin, fertility, IVF, miscarriages, prostaglandins, IN-VITRO FERTILIZATION, LOW-DOSE ASPIRIN, ANTIPHOSPHOLIPID ANTIBODIES, EMBRYO-TRANSFER, RECURRENT MISCARRIAGE, PREGNANCY RATES, PROSTAGLANDIN ENDOPEROXIDES, AUTOIMMUNE ANTIBODIES, INVITRO FERTILIZATION, UTERINE PERFUSION",
author = "O. Ozturk and Michael Greaves and Templeton, {Alexander Allan}",
year = "2002",
doi = "10.1093/humrep/17.5.1146",
language = "English",
volume = "17",
pages = "1146--1148",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "OXFORD UNIV PRESS",
number = "5",

}

TY - JOUR

T1 - Aspirin dilemma. Remodelling the hypothesis from a fertility perspective

AU - Ozturk, O.

AU - Greaves, Michael

AU - Templeton, Alexander Allan

PY - 2002

Y1 - 2002

N2 - Many clinical trials in obstetrics have failed to demonstrate improved outcomes with low-dose aspirin. This is not entirely surprising as prescribing aspirin for compromised tissue perfusion without insight into underlying pathology inevitably leads to suboptimal outcomes. We argue that a mismatch between the aspirin dose and the underlying pathology of altered tissue perfusion is the key factor to this failure. Based on this groundwork, we address the question of how best to optimize the dose of aspirin for use in fertility management, by providing examples from the assisted conception and recurrent miscarriage settings.

AB - Many clinical trials in obstetrics have failed to demonstrate improved outcomes with low-dose aspirin. This is not entirely surprising as prescribing aspirin for compromised tissue perfusion without insight into underlying pathology inevitably leads to suboptimal outcomes. We argue that a mismatch between the aspirin dose and the underlying pathology of altered tissue perfusion is the key factor to this failure. Based on this groundwork, we address the question of how best to optimize the dose of aspirin for use in fertility management, by providing examples from the assisted conception and recurrent miscarriage settings.

KW - aspirin

KW - fertility

KW - IVF

KW - miscarriages

KW - prostaglandins

KW - IN-VITRO FERTILIZATION

KW - LOW-DOSE ASPIRIN

KW - ANTIPHOSPHOLIPID ANTIBODIES

KW - EMBRYO-TRANSFER

KW - RECURRENT MISCARRIAGE

KW - PREGNANCY RATES

KW - PROSTAGLANDIN ENDOPEROXIDES

KW - AUTOIMMUNE ANTIBODIES

KW - INVITRO FERTILIZATION

KW - UTERINE PERFUSION

U2 - 10.1093/humrep/17.5.1146

DO - 10.1093/humrep/17.5.1146

M3 - Article

VL - 17

SP - 1146

EP - 1148

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 5

ER -